---
title: "Pathology Primers"
description: "Disease overviews for pharmacometricians covering pathophysiology, biomarkers, treatment regimens, and PK/PD modeling approaches."
---

Concise disease overviews for pharmacometricians â€” pathophysiology, biomarkers, drug regimens, and modeling approaches.

::: {.grid}

::: {.g-col-12 .g-col-md-6 .index-card}
[Autoimmune Diseases](autoimmune/giant-cell-arteritis/index.qmd){.card-title}
GCA, psoriasis, and rheumatoid arthritis.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Viral Infections](viral/hiv/index.qmd){.card-title}
HIV/AIDS and viral disease pharmacology.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Bacterial Infections](bacterial/bacterial-infection/index.qmd){.card-title}
Tuberculosis and antibacterial treatment strategies.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Cancer](cancer/lung-cancer/index.qmd){.card-title}
Lung and skin cancer pharmacology and treatment.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Neurological Diseases](neurological/alzheimer/index.qmd){.card-title}
Alzheimer, Parkinson, and schizophrenia.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Diabetes](diabetes/index.qmd){.card-title}
Metabolic disease, glucose regulation, and antidiabetic drugs.
:::

:::

## Disease facts that are good to know

Each primer provides a concise, high-level summary of a disease relevant to pharmacometricians, focusing on biomarkers, drug regimens, and modeling approaches.

Typical structure for disease "XYZ":

1. What is XYZ?
  * Disease definition & pathophysiology
  * Commonly used Pharmacodynamic (PD) Models (e.g., disease progression models, target engagement)
2. Patient characteristics
  * Typical patient population
  * Risk factors & disease progression indicators
3. Diagnosis & biomarkers
  * Key Clinical Biomarkers (e.g., lab values, thresholds, imaging)
  * Disease Severity Classification (if applicable, e.g., staging systems)
4. How can XYZ be treated?
  * Treatment aim (PD-targets)
  * Common Drug Classes & Regimens
    * Mechanism of Action (MoA)
    * First-line vs. second-line treatments
    * Dose Adjustments (e.g., renal/liver impairment, pediatrics)
  * Commonly used PK-models
